IL‑17F promotes osteoblastic osteogenesis via the MAPK/ERK1/2 signaling pathway

Abstract

Osteoimmunology is a field that focuses on the interactions between the skeletal and immune systems, and has become a focus of research over the years. The role of interleukin (IL)-17F, a proinflammatory cytokine, in bone regeneration and its signal transduction are not completely understood. The aim of the present study was to evaluate the function of IL-17F and the possible mechanisms underlying IL-17F in osteoblasts in vitro. Osteoblasts derived from newborn rats were treated with various concentrations of IL-17F. The pro-osteogenic effects of IL-17F were assessed at the cellular and molecular level. The results demonstrated that IL-17F promoted osteoblast proliferation, differentiation and mineralization. Reverse transcription-quantitative PCR and western blotting indicated that IL-17F treatment upregulated osteogenesis-related factors, including bone morphogenetic protein-2, Runt-related transcription factor-2 (Runx2) and Osterix, and downregulated Noggin compared with the control group. Subsequently, whether the IL-17F receptors, IL-17 receptor (IL-17R) A and IL-17RC, served a role in the effects of IL-17F on osteoblasts was investigated. The mRNA expression levels of IL-17RA and IL-17RC were upregulated in IL-17F-treated osteoblasts compared with control osteoblasts. Furthermore, U0126, a MAPK/ERK1/2 inhibitor, was utilized to investigate the mechanisms underlying IL-17F. The results indicated that compared with the control group, IL-17F increased the protein expression of phosphorylated-ERK1/2, Runx2 and Osterix, whereas U0126 reversed IL-17F-mediated effects. Collectively, the results of the present study suggested that IL-17F promoted osteoblastic osteogenesis via the MAPK/ERK1/2-mediated signaling pathway. IL-17F promoted osteogenesis, including proliferation, differentiation and mineralization activity, indicating that IL-17F may serve as a potential therapeutic target for osteoblast-mediated bone loss disease.

Thyrotropin inhibits osteogenic differentiation of human periodontal ligament stem cells

“…Activation of the store‐operated calcium channel promotes mesenchymal osteogenic differentiation 43,44 . IL‐17 signaling pathway influences osteogenic differentiation of MSCs 45–47 . TNF signaling pathway can trigger osteogenic differentiation of MSCs 48,49 .…”

“…43,44 IL-17 signaling pathway influences osteogenic differentiation of MSCs. [45][46][47] TNF signaling pathway can F I G U R E 6 Functional clustering and pathway analysis of differentially expressed genes in PDLSCs under the effect of TSH Some of the differentially expressed genes are related to bone homeostasis and remodeling. (A) Gene ontology (GO) enriched top10 chord diagram.…”

Osteogenic Efficacy of Human Trophoblasts-Derived Conditioned Medium on Mesenchymal Stem Cells

“…Moerman et al showed that aging affects the differentiation capability of MSCs by downregulating the adipogenesis-related cytokines [ 31 ], thus contributing to bone remodeling and upregulating the expression of adipogenesis-related cytokines [ 32 ]. Thus contributing to bone remodeling disorders.…”

“…Several recent studies have indicated the positive effects of IL-17 on bone formation. It has been shown that the IL-17F cytokine induces osteogenesis via the MAPK signaling cascade [ 31 ]. Croes et al reported the function of IL-17 in BMP2-induced ectopic bone formation [ 38 ].…”

Analysis of Zinc and Stromal Immunity in Disuse Osteoporosis: Mendelian Randomization and Transcriptomic Analysis

“…IL-17F promotes osteogenesis, including proliferation, differentiation, and mineralization activities, by upregulating BMP-2, Runx2, and Osterix expression and downregulating Noggin expression. [60][61][62] The SLC39A family of metal transporters was identified through homologies with ZIP proteins. ZIP14 was the encoding protein of SLC39A14.…”